Y-mAbs aims for $92M IPO

Y-mAbs Therapeutics Inc. (New York, N.Y.) filed to raise up to $92 million on Aug. 24 in an IPO on NASDAQ underwritten by BofA Merrill Lynch, Cowen, Canaccord Genuity and BTIG.

Y-mAbs hopes to submit BLAs next year for two antibodies that are now in pivotal trials to treat pediatric neuroblastoma indications. Each program has Orphan Drug, rare pediatric disease and breakthrough therapy designations...